Ten deals. Twenty-five billion dollars. Five months. Eli Lilly announced agreements on May 26 to acquire three privately held vaccine developers in simultaneous transactions totaling up to $3.83 billion: Curevo ($1.5 billion, shingles vaccine), LimmaTech Biologics ($780 million, bacterial vaccines for antimicrobial resistance pathogens), and Vaccine Company ($1.55 billion, Epstein-Barr virus nanoparticle vaccine). These are Lilly’s 8th, 9th, and 10th deals of 2026. Total announced M&A value this year now exceeds $25 billion. CSO Daniel Skovronsky said the deals “reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” citing decades of evidence linking common infections to downstream neurological disease, cancer, and infertility. Lilly is moving upstream from treating chronic disease to preventing it. Fierce Biotech described the pace as “almost weekly” and noted it shows “no sign of letting up.” ASCO opens tomorrow. Revolution Medicines’ plenary is Saturday.
Top Story: Lilly Acquires Three Vaccine Developers for $3.83B Combined
What Happened: Eli Lilly announced on May 26 agreements to acquire three privately held vaccine companies in simultaneous transactions.
Curevo: Challenging Shingrix with a Better-Tolerated Shingles Vaccine (Up to $1.5B)
Curevo is developing amezosvatein, a shingles vaccine using a next-generation synthetic adjuvant. In Phase 2 testing, amezosvatein matched the immunogenicity of the standard shingles shot—GSK’s Shingrix—while reducing activity-limiting side effects. A Phase 2 extension enrolled 640 additional participants in 2025. Curevo raised $110 million last year to fund the extension.
Why This Matters: GSK’s Shingrix is a nearly $5.6 billion franchise and one of the most commercially successful vaccines in the world. But it has a well-documented tolerability problem. A significant number of patients report injection-site reactions, and many report systemic reactions including fever, fatigue, and headache that limit activity for one to two days after vaccination. These side effects are driven by the AS01B adjuvant system.
The tolerability issue has practical consequences. Shingles vaccination rates remain lower than public health targets, partly because patients who experienced side effects after the first dose are reluctant to return for the second. Physicians who have seen patients react to Shingrix are less aggressive in recommending it. The market is large—approximately one million U.S. shingles cases per year—and underpenetrated specifically because of the tolerability barrier.
Curevo’s synthetic adjuvant approach is designed to maintain the robust immune response that makes Shingrix effective while reducing the reactogenicity that limits its uptake. If Phase 3 data confirm the Phase 2 profile—matched immunogenicity with fewer activity-limiting side effects—amezosvatein would offer the same protection with a meaningfully better patient experience. That is a clear value proposition for patients, physicians, and payers.
LimmaTech Biologics: Vaccines Against the Antimicrobial Resistance Crisis (Up to $780M)
LimmaTech is developing vaccines against bacterial pathogens where rising antimicrobial resistance is closing therapeutic options.
Lead program LTB-SA7 is in Phase 1 for Staphylococcus aureus, the leading cause of surgical infections worldwide. S. aureus infections kill tens of thousands of patients annually and impose enormous hospital costs. Methicillin-resistant S. aureus (MRSA) is one of the most significant antibiotic-resistant threats globally. A vaccine that prevents S. aureus infections before they occur would reduce both the human toll and the selective pressure that drives further resistance.
LimmaTech’s pipeline also includes vaccines for Neisseria gonorrhoeae and Chlamydia trachomatis—two sexually transmitted infections where antibiotic resistance is a growing concern. Gonorrhea in particular has developed resistance to nearly every antibiotic class used against it, and the WHO has classified it as a high-priority pathogen for new therapeutic and preventive development. A preventive vaccine would address a public health challenge that therapeutic approaches are increasingly unable to manage.
The platform targets bacterial toxins and superantigens to generate broad, durable immune responses. This is a different approach from traditional bacterial vaccines, which often target surface proteins that bacteria can mutate to evade. Targeting the toxins that cause disease rather than the structural components of the bacteria may produce a more durable vaccine response that is harder for bacteria to escape through mutation.
The antimicrobial resistance dimension adds urgency that extends beyond any single pathogen. The WHO estimates that drug-resistant infections contribute to nearly 5 million deaths annually worldwide. As the therapeutic pipeline for new antibiotics remains thin—few pharmaceutical companies invest in antibiotic development because the commercial returns are poor—vaccines that prevent infections before they occur become the most viable strategy for containing the AMR crisis. Lilly’s entry into this space through LimmaTech aligns with both public health need and the company’s prevention-over-treatment thesis.
Vaccine Company: Preventing EBV and Its Downstream Consequences (Up to $1.55B)
Vaccine Company is developing a five-antigen Epstein-Barr virus vaccine using proprietary Vivo Nanoparticle technology. The program is currently preclinical and Phase 1 ready. The company received an ARPA-H grant in 2024.
Why EBV Matters: Epstein-Barr virus is now established as the leading cause of multiple sclerosis. A landmark 2022 study in Science demonstrated that EBV infection increases the risk of MS by 32-fold. EBV is also linked to several cancers including nasopharyngeal carcinoma and Hodgkin lymphoma, as well as other autoimmune conditions. Approximately 95% of adults worldwide are infected with EBV, making it one of the most ubiquitous human viruses.
A vaccine that prevents EBV infection could prevent multiple sclerosis before it starts. This is not treating MS after diagnosis—it is eliminating the viral trigger that causes it. The MS drug market generates tens of billions of dollars annually in global revenue. An EBV vaccine that reduces MS incidence would be one of the most valuable preventive medicines ever developed, even as it would reduce the downstream market for MS treatments.
Skovronsky’s framing was deliberate: “Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility. And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention.”
The Strategic Logic: Prevention Over Treatment
The three vaccine acquisitions represent a new strategic front for Lilly. The company has not been in the vaccine business for decades. Entering now, with three simultaneous acquisitions spanning viral prevention (shingles, EBV) and bacterial prevention (staph, gonorrhea, chlamydia), signals a strategic thesis that prevention is more valuable than treatment.
The logic connecting vaccines to Lilly’s existing franchise is clearer than it might appear on the surface. Lilly’s GLP-1 obesity drugs treat the consequences of metabolic disease. Its narcolepsy acquisition (Centessa) treats a chronic neurological condition. Its oncology pipeline (Ajax, CrossBridge) treats cancers after they develop. The vaccine acquisitions move one step further upstream: preventing the infections that cause the diseases Lilly would otherwise need to treat. If EBV causes MS, preventing EBV is more valuable than developing the next MS drug. If surgical infections kill patients and drive AMR, preventing S. aureus is more valuable than developing the next antibiotic.
Our Pro brief analyzes why Lilly’s pivot to prevention fits the “prevent disease at its source” thesis, how amezosvatein could reshape the $5.6B shingles market, and what 10 acquisitions spanning seven therapeutic areas means for Lilly’s organizational bandwidth heading into the December 7 Investment Community Meeting. [Details below.]
Lilly’s 2026 M&A: The Full Ledger at 10 Deals
The three vaccine acquisitions bring Lilly’s 2026 deal count to 10 and total announced value to approximately $25.9 billion across five months:
Orna Therapeutics: $2.4 billion (in vivo CAR-T, autoimmune). Centessa Pharmaceuticals: $7.8 billion (narcolepsy/OX2R). Kelonia Therapeutics: Up to $7 billion (in vivo CAR-T, myeloma). CrossBridge Bio: Up to $300 million (dual-payload ADC). Ajax Therapeutics: Up to $2.3 billion (Type II JAK2, myelofibrosis). Profluent Bio: Up to $2.25 billion in milestones (AI gene editing collaboration). Engage Biologics: Undisclosed (non-viral DNA delivery). Curevo: Up to $1.5 billion (shingles vaccine). LimmaTech Biologics: Up to $780 million (bacterial vaccines, AMR). Vaccine Company: Up to $1.55 billion (EBV nanoparticle vaccine).
The breadth is as notable as the volume. Lilly has entered or expanded in seven therapeutic areas in under five months: obesity/metabolic, oncology, cell therapy, narcolepsy/neuroscience, gene editing/delivery, myelofibrosis/hematology, and now infectious disease prevention. Three technology platforms have been acquired (in vivo CAR-T, non-viral DNA delivery, AI-designed recombinases). Three vaccine programs have been added spanning three distinct pathogen categories.
No other pharmaceutical company has executed this volume, breadth, and pace of dealmaking in a comparable timeframe. The closest historical precedent may be the Pfizer/Wyeth era or the Roche/Genentech integration, but those were single transformative mergers rather than 10 separate transactions across seven therapeutic areas in five months. Lilly’s approach is fundamentally different: rather than one large acquisition that reshapes the company overnight, it is executing a series of targeted deals that collectively build a diversified platform across multiple growth vectors. Each deal is sized to address a specific strategic gap. Together, they constitute the most ambitious pipeline construction effort in recent pharmaceutical history.
The December 7 Investment Community Meeting will be the first opportunity for management to present a unified strategic narrative that integrates all 10 acquisitions into a coherent growth framework. Investors will want to understand the integration plan, the prioritization across therapeutic areas, the capital allocation going forward, and whether the organizational structure can support this level of simultaneous activity.
Verve Base Editor Shows Early Promise in Cholesterol
BioSpace reported that Lilly’s investment in Verve Therapeutics is producing returns: a base editing approach to permanently lower cholesterol showed positive results in an early clinical study. Base editing makes precise single-letter changes to DNA without cutting both strands (unlike CRISPR), potentially reducing the risk of unintended genetic changes.
Why This Matters: If the approach works at scale, a single treatment could permanently lower LDL cholesterol, eliminating the need for daily statins or periodic PCSK9 injections. This complements the new AHA/ACC LDL guidelines and the cardiovascular growth cycle we have been tracking throughout May. It also connects to Lilly’s broader prevention thesis: a one-time gene edit that permanently reduces cardiovascular risk is the ultimate form of disease prevention at the molecular level. Combined with the vaccine acquisitions, the Verve data reinforces Lilly’s strategic direction—moving upstream from chronic disease management to permanent prevention through both immunological and genetic approaches.
Strategic Themes
1. Lilly Is Building the Most Diversified Pharmaceutical Platform of the Modern Era
Ten acquisitions across seven therapeutic areas in five months. No other company has built this breadth this quickly. The GLP-1 cash generation engine—Mounjaro and Zepbound together represent the largest pharmaceutical revenue franchise on earth—makes the financial deployment possible. Lilly raised its full-year guidance to $82 billion to $85 billion on the back of Q1 results that crushed expectations. That cash flow underpins the $25.9 billion in M&A commitments. Whether the organizational bandwidth supports integrating 10 companies simultaneously—while launching Foundayo, filing for a diabetes indication, managing the retatrutide TRIUMPH program, and running the existing commercial franchise—is the open question that the December 7 Investment Community Meeting will need to address convincingly.
2. The Vaccine Thesis Is a Bet on Prevention as the Next Frontier of Pharma Value Creation
Treating disease after it develops has been pharma’s business model for a century. Lilly is betting that preventing disease before it starts—through vaccines that block the infections that cause chronic conditions—is the next frontier. If EBV vaccines prevent MS, if shingles vaccines with better tolerability increase coverage rates, if AMR vaccines reduce surgical infections, the value creation is enormous because the prevented conditions are expensive to treat over a lifetime. The commercial returns are longer-dated (none of these vaccines will generate revenue before 2028 at the earliest), but the strategic positioning is forward-looking in a way that few pharmaceutical M&A campaigns have been.
3. The Shingrix Challenge Could Be the Most Commercially Significant of the Three Deals
Curevo’s amezosvatein is the most advanced program (Phase 2 extension) and targets the largest existing market (Shingrix at $5.6 billion). If Phase 3 confirms matched immunogenicity with reduced reactogenicity, amezosvatein would be the first real competitive threat to one of the most successful vaccine franchises in the world. GSK will not cede share without a fight—expect aggressive pricing, physician outreach, and data generation in response. But the tolerability story is hard to counter if the Phase 3 data hold.
4. ASCO Opens Tomorrow—and Saturday’s Plenary Is the Year’s Defining Oncology Moment
Revolution Medicines presents full Phase 3 RASolute 302 data on Saturday May 31. The topline (13.2 months OS versus 6.7 months, HR 0.40) is known. PFS data, subgroup analyses, survival curves, and safety details will determine label scope, clinical adoption, and the commercial trajectory. Truist projects Q3 approval under CNPV. We begin daily ASCO coverage tomorrow.
Frequently Asked Questions
What are the three vaccine companies Lilly acquired?
Curevo (up to $1.5B, shingles vaccine with next-generation synthetic adjuvant), LimmaTech Biologics (up to $780M, bacterial vaccines targeting S. aureus, gonorrhea, and chlamydia for AMR), and Vaccine Company (up to $1.55B, Epstein-Barr virus five-antigen nanoparticle vaccine). Combined value: up to $3.83 billion.
How many deals has Lilly done in 2026?
Ten. Total announced value approximately $25.9 billion across five months spanning obesity, oncology, cell therapy, narcolepsy, gene editing, myelofibrosis, and now infectious disease prevention.
Why is Lilly entering the vaccine business?
CSO Skovronsky said the deals “reflect a deliberate strategy to prevent disease at its source rather than treat its consequences.” EBV is established as the leading cause of MS. S. aureus is the leading cause of surgical infections. Shingles affects approximately one million Americans annually. The vaccine strategy moves Lilly upstream from treatment to prevention.
How does Curevo compare to Shingrix?
Phase 2 data showed amezosvatein matched Shingrix’s immunogenicity while reducing activity-limiting side effects. The tolerability improvement is attributed to a synthetic adjuvant versus Shingrix’s AS01B adjuvant system. Phase 2 extension (640 participants) completed in 2025. Phase 3 data will determine whether the profile holds at scale.
What is the EBV vaccine significance?
EBV infection increases MS risk by 32-fold (Science, 2022). Approximately 95% of adults worldwide are infected. A vaccine that prevents EBV could prevent multiple sclerosis before it starts, potentially reducing one of the most significant neurological disease burdens globally. The program is preclinical and Phase 1 ready.
What is the Verve base editing data?
A base editing approach to permanently lower cholesterol showed positive results in an early clinical study. Base editing makes single-letter DNA changes without cutting both strands. If it works at scale, a single treatment could permanently replace daily statins or periodic PCSK9 injections.
When is ASCO?
Opens tomorrow (May 29) through June 2 in Chicago. Revolution Medicines plenary session Saturday May 31. Full Phase 3 RASolute 302 data. We begin daily coverage tomorrow.
When is the Lilly Investment Community Meeting?
December 7, 2026. The meeting will be the first opportunity for management to present an integrated strategy across all 10 acquisitions.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly’s Vaccine Bet. We analyze why preventing shingles, EBV, and AMR infections fits the “prevent disease at its source” thesis, how the prevention-over-treatment model creates long-term value, and what the pipeline development timelines mean for when these programs could contribute revenue.
Shingrix vs. Curevo. We break down how a synthetic adjuvant could reshape the $5.6 billion shingles market, model the vaccination rate expansion that improved tolerability could drive, and assess GSK’s competitive response options.
Ten Deals, One Year. We compile the full strategic map of Lilly’s 2026 M&A campaign—10 deals, 7 therapeutic areas, 3 technology platforms, 3 vaccine programs—and assess whether the organizational bandwidth exists to integrate this many acquisitions simultaneously while running the most important product launch (Foundayo) and the most promising late-stage program (retatrutide) in the company’s history.
Plus: LimmaTech AMR vaccine platform analysis, EBV/MS prevention thesis, Verve base editing cardiovascular implications, ASCO opens tomorrow, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
